Starch catabolism leading to high glucose level in blood is highly problematic in chronic metabolic diseases, such as type II diabet es and obesity. α-Amylase catalyses the hydrolysis of starch, increasing blood sugar conc entration. Its inhibition represents a promising therapeutic approach to control hyperglycaemia. However, only few drug-like molecule inhibitors wit hout sugar moieties have been discovered so far, and little information on the enzymatic mechanism is available. This work aims at the discovery of novel small α-amylase binders using a systematic in silico methodology. 3D-pharmacophorebased high throughput virtual screening of small compounds libraries was performed t o identify compounds with high α-amylas e affinity. Twenty-seven compounds were selected and biologically tested, revealing IC 50 values in the micromolar range and ligand efficiency higher than the one of the bound form of acarbose, which is used as a reference for α-amylase inhibition.
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Introduction
Metabolic diseases like obesity and type II diabetes are characterized by high levels of blood glucose. 1 One of the most attractive targets for the development of novel therapeutic agents and controlling the glucose level in the blood is α-amylase. 2, 3 α-Amylases (1,4-α-D-glucan-4-glucanohydrolase, EC 3. 2.1.1)
are endoamylases broadly distributed throughout the microbial, plant and animal kingdoms , 4 , 5 which catalyze hydrolysis of starch and glycogen. 6 In humans, α-amylase is expressed as two isoforms, secreted from salivary glands and pancreas, respectively. These enzymes play a role in digestion of polysaccharides like starch, the main source of gluc ose in human diet . [7] [8] [9] Human salivary α-amylase (HSA) initiates the hydrolysis of α-(1, 4) glycosidic bonds in the dietary starch into smaller oligosaccharides. 10 Further digestion of carbohydrates takes place in the gut under control of human pancreatic α-amylase (HPA ). 11 Henc e, hydrolysis of polymeric starch by HSA and HPA produces maltos e, maltotriose and other oligomers, which are then degraded into glucose by α-gluc osidase. 12 Therefore, α-amylase inhibitors can control the break down of dietary starch into smaller oligomers , 13 with the purpose of delaying glucose absorption to a rate the body can handle and hence decreasing the postprandial hyperglycemia. 2, 14, 15 α-Amylase inhibition was recently observed with natural products extracted from Hungarian sour cherries. 16 But peptide-based compounds were the first reported highly potent α-amylase inhibitors. [17] [18] [19] Carbohydrate-based inhibitors have been studied intensively as α -amylase inhibitors, showing a similar range of potency as the peptide-based inhibitors. 7 Acarbos e, a natural metabolit e of Streptomyces sp., has been used in the treatment of type II dia betes and was shown to inhibit α-amylase and α-glucosidase but with undesirable gastrointestinal disturbances . 20 These side effects arise as a c onsequence of maltos e ferment ation which accumulates due to α -glucosidase inhibition. Therefore, a non-carbohydrate-based α-amylase inhibitor is expected to be better agent to restrain postprandial hyperglycemia since it would not lead to abdominal accumulation of maltose . 21 In humans, α-amylases secreted from pancreas and saliva are two very closely related isoforms with 97 % sequence identity (92 % in the catalytic domains). [22] [23] [24] The active site is located at a large V-shaped cavity in the catalytic domain to accommodate the natural substrate, starch. 25 Subsites in this binding cleft are denoted with the numbers from -4 to +3, according to Davies et al. 7, 26, 27 The cleavage of the natural substrate takes place between subsites -1 and +1, where catalytic residues Asp197, Glu233 and Asp300 play a central role in the hydrolysis mechanism.
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In this work, we aim at identifying novel small non-sugar drug-like molecules binding to α-amylas e and inhibiting its activity. To reach t his objective, a structure -based approach was developed using 3D-pharmacophore models and virtual screening. 
Resul ts and Di scussion

Development and Validation of the 3D-Pharmacophore Model
First, all inhibitors co-crystallized with α-amylase available from the P rotein Data Bank (PDB ) 29, 30 were collected in order to build a pharmacophore model that compiles all essential features required for an optimal ligand-enzyme interaction in the catalytic pocket. Due to their different binding areas further away from the enzymatic active site, peptide-based inhibitors were excluded from this preliminary analysis. 25, 31 Assuming the cleavage site of α-amylase (at subsites -1 and +1) is a central domain for substrat e binding, particular attention was paid t o interactions observed between the enzyme and t he investigated ligands in this region. The study of c arbohydrate-based inhibitor binding modes shows that one water molecule (HOH-746) is highly conserved among available crystal structures in t he P DB. This molecule often stabilizes co-crystallized ligands in t he enzyme by bridging H -bonds bet ween enzyme and inhibitor.
Superposing the studied crystal structures (S upplementary data, Fig. S1 ) revealed t hat HOH-746 is located nearly at the same position in all investigated macromolecules. This interaction was included in our 3D pharmacophore model to retain this particular environment of the pocket , surrounded by residues Glu233 and Lys200 (Figure 1 ).
The reliability of the developed model (i.e. ability to discriminate between inhibitors and non-inhibitors)
was assessed and improved using a dataset of 19 active compounds and 55 known inactive compounds assembled from the literature and the Chembl database (see supplementary data, Tables S1 and S2).
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Multi-conformational screening of these compounds was carried out and the signal -noise ratio was determined using a Rec eiver Operating Characteristics (ROC) curve. 33 Iterative development and validation steps yielded a 3D-pharmacophore model with good early enrichment factor value (EF 1% = 3.9).
This model exhibited an excellent sensitivity in retrieving 63 % (12 out of 19) of the active compounds while being highly restrictive, i.e. excluding 98 % (54 out of 55) of inactive compounds. Table 1 . 
Virtual Screening
After validation of the 3D pharmacophore, the model was used for virtual screening of 1,762,189 drug-like compounds from commercial libraries (Analyticon, Asinex, Life chemicals, Chembridge, Specs, Bionet, and P restwick). The 3D model picked 5, 748 hits, which is 0. 32 % of the full library. Retrieved hits were ranked using the pharmacophore fit and the first 3,000 compounds were ret ained. Subsequently, 2D
descriptors were used (i.e. HBD ≤ 2 -5, HBA ≤ 10, Mol. Wt. ≤ 700 and ClogP ≤ 5) to exclude non drug-like compounds and select 2,292 molecules for further processing. In order to reduce the amount of inhibitors to handle prior to biological ex periments, two different strategies were applied: virtual docking and structural clustering. On one hand, software GOLD 5.1 36 was used to dock all selected virtual hits into the α-amylase active site (PDB code 3OLE ). 7 With LigandScout, poses were minimized inside the enzymatic pocket (using the MMFF94 force field) 37 and prioritized based on their ability to geometrically fulfill the features compiled in the 3D-pharmacophore. Careful visual inspection was undertaken for each compound conformation with the highest fit scores and the 30 most promising structures were selected for the next step. On the other hand, all 2,292 virtual hits were subjected to structural clustering with the software Jklustor 5.8.0. 38 The 17 candidates with the highest structural diversity wer e selected for further investigation. Based on their availability at the vendors, 9 virtual hits were purchased for biological testing Kinetic assay was carried out using 2 -chloro-4-nitrophenyl-4-O-β-D-galactopy ranosylmaltoside (GalG 2 CNP) as a substrate for HAS. 39 The released chromogenic product chloronitrophenol (CNP) was continuously monitored at 400 nm with respect to time. Using this method, the inhibitory effect of compounds 2 -9 was evaluated (1 was discarded due to its low solubility). In this assay, compounds 2, 3, and 4 revealed promising inhibition potencies against HSA with IC 50 ≤ 300 µM ( 50 . [40] [41] [42] The active compounds identified by virtual screening own higher LE compared t o the bound acarbose ( Table 2 ). These small molec ules are therefore considered promising compounds that can be used as a structural query to lead the development of novel potent α-amylase inhibitors. HA stands for number of heavy atoms, ND stands for inactive at 200 µM and NT means not tested due to insolubility.
* Bound acarbose (pseudo hexasaccharide) in the active site of HSA (PDB: 1MFV) 43 was used for LE calculations. All experiments were repeated three times and the obtained IC50 did not vary more than 5 % Re-docking of the active compounds in the binding site of α -amylase was conducted to rationalize their structure-activity relationships (SA R) using their potential binding modes and comparing them to the cocrystallized inhibitor acarviostatin 0II3 (K i ~ 14 nM, PDB code of enzyme 3OLE). 7 The ideal accommodation in subsites -1 and +1 of compound 2 can explain the inhibitory effect of this small molecule. Indeed, the three ring-backbone of this inhibitor fully occupies subsites -2, -1, and +1, and partially +2. This interaction with the cat alytic core of t he cavity is similar to the one of acarviosine, the subunit of acarviostatin 0II3 and acarbose holding a valienamine and a 4,6-dideoxyglucose fragments.
This essential scaffold of acarbose and other trestatin family inhibitors interacts with the c entral subsites -1 and +1. Our study shows that the hydroxyl group of resorcinol in compound 2 can form two H-bonds with His 305 and the c atalytic residue Asp300, in subsite -1. The side chain of Glu233, another catalytic residue in subsite +1, can form a H-bond with the amino group linking to the thiazole and phenolic rings of compound 2. A n additional H-bond can be formed bet ween t he phenolic hydroxyl group and Tyr151 near subsite +2. Interestingly, in t he propos ed binding mode of compound 2, the thiazole moiety occupies subsite -1, just like valienamine, and stabilizes the inhibitor via hydrophobic cont act with the side chain of Tyr62. Lipophilic residues Leu165, Trp58 near subsite -2, on one hand, and Ile235 and Leu162 near subsite +1, on the other hand, can form hydrophobic contacts with the aromatic resorcinol and phenolic rings, respectively. These int eractions can explain the good stabilization of compound 2 in the catalytic core of α-amylase ( Figure 3) . Similarly, our docking study shows that compound 3 also occupies t he cat alytic core (subsites -1 and +1) and protrudes to the nearby subsites. Superposition with acarviostatin II03 highlights a similar binding mode. The predicted conformation of 3 suggests that two H-bonds can be formed between the catalytic residues Asp300 and Glu233 and the hydroxyl groups of t wo p-cresol rings. Methyl group of the central pcresol fragment of 3 can point to subsite -3 and form hydrophobic contact with the side chain of Thr163, stabilizing the inhibitor in the pocket. The other two p-cresol rings can form hydrophobic contacts in subsite -2 with Leu165 and Trp59, subsite +1 with Leu162 and Ile235, and near subsite +2 with Tyr151.
Although compound 3 is spanning from subsites -2 to + 2, its inhibitory potency (IC 50 = 200 µM) was lower compared to compound 2 (IC 50 = 138 µM). This can be due to (i) the fewer amount of H-bonds that could be detected compared to the binding mode of 2, and (ii) the thiazole ring of 2 that is better accommodated than the p-cresol of 3, and could play an import ant role in stabilization of the ligand in subsite -1 ( Figure   3 ).
Compound 4 shows a weaker inhibitory potency (IC 50 ~ 300 µM) even though the docking study shows it can occupy subsites -3 to +2. In our model, the catalytic residue Asp300 forms a positive ionizable interaction with the amino group of the piperidine moiety, contributing to the stabilization of this ligand in the cavity. This inhibitor is stabilized inside the pocket by forming hydrophobic contact s with lipophilic residues Thr163, Tyr62, Leu165, Leu162, and Ile235. Nevertheless, the presence of the nitro groups seems to affect its binding and the lack of adequate interaction with the catalytic residues can play a crucial role in the weaker inhibit ory potency of 4.
Similarity Search
Compound 2 represents the most active competitive inhibitor with the highest ligand efficiency identified in this virtual screening. Interestingly, 2 is also an allosteric inhibitor of the fructose 1,6-bisphosphatase (IC 50 = 11 μM) 44 , an enzyme involved in gluconeogenesis. Thus, this chemical scaffold has the potential to act as dual inhibit or and to decrease glucose levels in blood. Therefore, this molecule was considered as a promising scaffold for the design of non-carbohydrate anti-diabetic molecule, and us ed as template to search for similar molecules with improved α-amylase inhibition.
Figure 4.
Overview of the similarity search approaches using compound 2 as query.
For the selection of chemical analogues, 2D and 3D similarity approaches were considered in parallel, (Figure 4 ). The first similarity search was conducted using the software ROCS 3.1.2 45 performing a high throughput 3D alignment of our library of 1,762,189 commercially available molecules. The 100 molecules with the best alignments (similarity with the lead query in terms of shape and chemical features) were selected and docked into the α -amylase active site (P DB: 3OLE). 7 A pharmac ophore model of compound 2 was us ed to prioritize the compounds able to create similar interactions with the enzyme. This step resulted in the selection of four compounds (22 -25, Table 3 ). The second approach was a 2D similarity search. This was performed with (i) an in -house collection of molec ules, from which 12 c ompounds were selected, and (ii) on the other side with the Chembridge library, from which 2 compounds were purchased (molecules 10 -21 & 26 -27, Table 3 ).
Overall, 18 analogues of 2 were selected for further biological evaluation. IC 50 values ranging from 40 µM to 4 mM were meas ured ( Table 3) . Interestingly, minor structural changes were shown to have a strong impact on the inhibitory potency of these compounds ( Figure 5 Interestingly, a dramatic decrease in activity is observed when ring B is substituted with a pyraz ole ring or Because of their small size, all analogues 10 -27 have a higher LE than the positive control (LE = 0.13).
The best inhibitor in the series 26 even displays an efficiency of 0.30 (   Table 4 ). 
Conclusions
Using a stepwise and rational structure -based 3D-pharmacophore approach, nine small molecules from a library of about one million commercial compounds were selected for biological testing. Three out of eight tested compounds revealed promising inhibitory potency (IC 50 ≤ 300 µM) and ligand efficiency (LE ≥ 0.15)
for furt her optimization. Using molecular docking, binding modes of the most active compounds were elucidated. It was shown that suitable orientations in the active site and occupancy of the productive subsites (-1, +1) were key parameters for an optimal inhibition.
Compounds 2 and 3 represent the most promising ligands identified in the pharmacophore -based virtual screening and are among the first small drug-like molecules reported as α-amylase inhibitors so far. While this project was in development, two other groups reported potent small mol ecules for α-amylase inhibition [47] [48] [49] . Interestingly, one of these compounds, a phloroglucinol derivative DDB T, 47 is a natural product with a very analogous scaffold to compound 3. This similarity confirms the rational of our strategy and the strength of our computer-aided methodology.
In a recent perspective study, Zhu et al. 50 report that a LE value of 0.3 for a drug -like compound In an evaluation of the quality of the analogues of compound 2, LE ratios and activity improvement were compared ( Thus, searching for analogues of 2 led to the identification of compounds with good activity ratio ( Table 4) . Among them, compound 26 display a 3-fold activity improvement compared to 2.
Thus, using the available structural information, a pharmacophore-based virt ual screening of commercial compounds was carried out, leading to the identification of small molecules and fragments with drug-like properties. Then, a second optimization step was conducted by searching for analogues of the best inhibitor, from which the SA Rs were analyzed with the support of molecular docking studies. All inhibitors discovered in this work are reported here for the first time as α-amylase inhibit ors. Consequently, the structural simplicity of the identified chemical structures and their low molecular weight is an important step in the design of new potent α-amylase inhibitors for the treatment of c hronic metabolic diseases such as type II diabet es and obesity.
Materials and methods
Pharmacophore creation and validation
Crystal structures (3OLD, 3OLE, 3OLG, 3OLI, 3IJ9, 3IJ7, 2QV4, 3BAJ, 3BAY, 1XH2, 1XD0, 1XD1, 1XH0, 1XCX, 1XCW, 1CPU, 1MFV, and 1OSE) of the HPA, HSA and porc ine pancreatic α-amylas es (PPA) cocrystallized with sugar-based inhibitors deposited in P DB 29, 30 were investigated using the platform LigandScout 3.1. 35, 51, 52 Binding modes of co-c rystallized inhibitors were analyzed in detail and their chemical interactions were translated into 3D pharmacophore models. Then, the resulting pharmacophores were aligned and used as a basis to develop a unique query for virtual screening .
Pharmacophore models created and developed were validated using 19 biologically known active and 55 inactive α -amylase inhibitors collected from Chembl database 53 and literature (Supplementary dat a, Tables S1 and S2 ). All these collected molecules were built and minimized using MOE 2010.10. 54 3D
coordinates were generated using CORINA 3.4. 55 The command-line tool idbgen was used to generate database files t o be used as inputs for screening in LigandScout 3. 
Molecular docking
All docking studies were performed using PDB entry 3OLE (resolution 1.55 Å) 7 using GOLD 5.1.
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Validation of docking was performed by reproducing the binding mode of the co-crystallized inhibitor, acarviostatin II03, with RMS D between the heavy atoms of the original co-crystallized ligand and the docked conformation ligand of 0.8 Å (Supplementary data, Fig. S2 ). Docking volume was defined by selecting all residues within 10 Å around the co-c rystallized inhibitor. Default docking paramet ers were used. All docking experiments were carried out using GoldScore 69 as scoring function with 100 % search efficiency. 100 Docking poses were generated for each compound. All conformations were imported into LigandScout 3.1 and minimized with MMFF94 force field 37 before analysis. 3D Pharmacophores were created in a volume within 7 Å sphere around the co-crystallized ligand. Visualization, analysis and illustration were done using LigandScout 3.1.
JKlustor 5.8.0 38 was used to perform structural similarity clustering for compounds obtained from virtual screening.
Biological testing
α-Amylase (E C 3. 2. was plotted as a function of inhibit or concentration (X axis). The data were fit using a standard fourparameter logistic nonlinear regression analysis of Grafit software. 70 The type of inhibition was determined by Lineweaver-B urk plot (Supplement ary data, Fig. 5 and Fig. 6 ). All experiments were repeated three times and the obtained IC 50 did not vary more than 5 %.
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